Low prevalence of human pegivirus 1 (HPgV-1) in HTLV-1 carriers from Belém, Pará, North Region of Brazil

• Autor(a) principal: Lima, Ana Beatriz Figueiredo de
• Data de Publicação: 2020
• Outros Autores: Sá, Keyla Santos Guedes de, Torres, Maria Karoliny da Silva, Soares, Luana da Silva, Resque, Hugo Reis, Azevedo, Vânia Nakauth, Feitosa, Rosimar Neris Martins, Monteiro, Jacqueline Cortinhas, Silva, Andrea Nazaré Monteiro Rangel da, Ribeiro, Andre Luis Ribeiro, Oliveira Filho, Aldemir Branco de, Vallinoto, Antonio Carlos Rosário, Machado, Luiz Fernando Almeida
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
• Texto Completo: https://patua.iec.gov.br/handle/iec/4091
• topic: Flaviviridae / isolamento & purificação; Infecções por Flaviviridae; Coinfecção; Vírus Linfotrópico T Tipo 1 Humano; Pegivírus Humano 1 (HPgV-1)

Introduction - Human pegivirus 1 (HPgV-1) is a single-stranded, positive-sense RNA virus belonging to the Flaviviridae family with limited cause-effect evidence of the causation of human diseases. However, studies have shown a potential beneficial impact of HPgV-1 coinfection in HIV disease progression. Human T lymphotropic virus-1 (HTLV-1) is a retrovirus known for causing diseases, especially in muscle and white blood cells, in approximately 5% of patients. Thus, this study aimed to investigate the potential effects of an HPgV-1 infection in patients carrying HTLV-1 in the state of Pará in the North Region of Brazil. Methods - A group of HTLV-1 carriers was compared to healthy controls. Blood samples were collected, data from medical regards were collected, and a questionnaire was administered. HPgV-1 and HTLV-1 positivity was determined by quantitative polymerase chain reaction (qRT-PCR). The data were analyzed to correlate the effects of HPgV-1 coinfection in HTLV-1 carriers. Results - A total of 158 samples were included in the study: 74 HTLV-1-positive patients (46,8%) and 84 healthy controls (53,2%). The overall HPgV-1 positivity rate was 7.6% (12/158), resulting in a prevalence of 5.4% (4/74) and 9.5% (8/84) in HTLV-1 carriers and healthy controls, respectively. No significant differences were found when comparing any clinical or demographic data between groups. Conclusion - This study indicated that the prevalence of HPgV-1 infection is low in HTLV-1 carriers in Belém, Pará, and probably does not alter the clinical course of HTLV-1 infection, however, further studies are still needed.